PARADIGM-HF
2014
Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality
In 8,442 patients with HFrEF (EF ≤ 0.40), sacubitril/valsartan reduced CV death or hospitalisation for HF compared with enalapril.
Result
Efficacy: CV death or HF hospitalisationHR 0.8
Below 1 favours sacubitril/valsartan, above 1 favours enalapril.
- Absolute difference
- 4.7 points
The absolute difference is derived from the event rates.
Also reported: All-cause mortality also reduced.
- Subtopic
- ARNI
- Design
- Double-blind RCT, terminated early
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- McMurray JJV, et al. N Engl J Med. 2014;371(11):993-1004.doi 10.1056/NEJMoa1409077
Discussion & critique
Run-in period excluded intolerant patients (~ 20 %), which may inflate efficacy estimates. ARNI replaced ACEi as preferred RAAS-blocker in HFrEF guidelines.